Intravenous Melanotan-II Activates Oxytocin Neurons in Rat Hypothalamus, Bypassing Local Inhibition

The central oxytocin system plays a crucial role in regulating social behaviors, and its dysregulation is linked to neurological conditions like autism. Melanocortins, a class of peptides, are known to stimulate this system and have been proposed as a potential therapeutic avenue. However, the precise mechanisms by which systemic melanocortin agonists influence oxytocin neurons are not fully understood. Previous studies have shown a direct inhibitory effect when melanocortin agonists are applied to oxytocin neurons in the supraoptic nucleus (SON). This creates a paradox: how can systemic administration be stimulatory if local action is inhibitory? This study aims to clarify how the melanocortin agonist Melanotan-II affects oxytocin neuronal activity and secretion when administered systemically, resolving the conflicting data on its mode of action.

Researchers investigated the effects of the melanocortin agonist Melanotan-II (MT-II) in rats. The study compared two routes of administration: intravenous (i.v.) and intranasal. To confirm the mechanism, some rats received an intracerebroventricular (i.c.v.) injection of the melanocortin antagonist, SHU-9119, prior to MT-II. Neuronal activation was measured by quantifying Fos protein expression, an immediate early gene product used as a marker for recent neuronal activity. They also used in-vivo electrophysiological recordings to measure the firing rate of identified magnocellular neurons in the supraoptic nucleus (SON) and microdialysis to measure local somatodendritic oxytocin release within the SON after i.v. MT-II administration.

Intravenous (i.v.) administration of Melanotan-II (MT-II) significantly increased neuronal activity, as indicated by a marked induction of Fos expression in the magnocellular neurons of the supraoptic (SON) and paraventricular nuclei (PVN) of the hypothalamus. This response was confirmed to be melanocortin receptor-mediated, as it was attenuated by prior administration of the antagonist SHU-9119. In contrast, intranasal administration of MT-II did not produce this effect. Electrophysiological recordings revealed that i.v. MT-II increased the firing rate of oxytocin neurons within the SON.

Critically, while neuronal firing increased, this activation did not trigger local somatodendritic oxytocin release within the SON itself, as measured by microdialysis. The study also noted that MT-II increased Fos expression in the caudal brainstem, suggesting an indirect pathway of activation. This supports the hypothesis that the stimulatory effects of systemic MT-II on hypothalamic oxytocin neurons are not direct, but are instead mediated by inputs from other brain regions, possibly the brainstem.